The board of directors greenlit the buyback program citing confidence in the biopharmaceutical firm's long-term growth trajectory. Chief Executive Officer Matthew Klein noted that the repurchase strategy allows the company to invest in itself while retaining the liquidity required to fund ongoing research programs and explore potential business development deals. Even with Tuesday's rally, the stock remains down 11% for the year, a performance gap the board evidently views as a temporary misalignment with the company's internal prospects. With a market capitalization of approximately $5.08 billion and roughly 80.9 million shares currently in public circulation, this authorization represents a significant commitment to returning capital to shareholders while the company navigates its current development cycle.
In section Market Quotes
PTC Therapeutics Authorizes $500 Million Stock Buyback
Shares of Warren, New Jersey-based PTC Therapeutics climbed 11% to $67.44 on Tuesday after the company revealed a plan to repurchase up to $500 million of its common stock. The move signals management's intent to capitalize on what it describes as a compelling valuation despite a year-to-date decline.
Comments (0)
No comments yet. Be the first!